Last reviewed · How we verify
QIVc
QIVc is a quadrivalent inactivated influenza vaccine that stimulates immune responses against four strains of influenza virus.
QIVc is a quadrivalent inactivated influenza vaccine that stimulates immune responses against four strains of influenza virus. Used for Seasonal influenza prevention in adults and children.
At a glance
| Generic name | QIVc |
|---|---|
| Also known as | Flucelvax Quadrivalent |
| Sponsor | Seqirus |
| Drug class | Inactivated influenza vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
QIVc contains inactivated (killed) influenza virus particles representing two influenza A subtypes (H1N1 and H3N2) and two influenza B lineages. The vaccine is administered intramuscularly and triggers both humoral and cellular immune responses, generating antibodies and T-cell immunity against the included viral strains to provide protection against seasonal influenza infection.
Approved indications
- Seasonal influenza prevention in adults and children
Common side effects
- Injection site pain or erythema
- Myalgia
- Headache
- Fatigue
- Low-grade fever
Key clinical trials
- Efficacy Study With QIVc in Pediatric Subjects (PHASE3)
- Flucelvax (TIVc or QIVc) Pregnancy Registry
- Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects (PHASE3)
- Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of QIVc in Subjects ≥2 to <18 Years of Age (PHASE3)
- Safety and Immunogenicity of Three Influenza Vaccines Adults Ages 18 and Older (PHASE3)
- Safety and Immunogenicity of Three Influenza Vaccines in Children Aged 4 Years Old to Less Than 18 Years Old (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- QIVc CI brief — competitive landscape report
- QIVc updates RSS · CI watch RSS
- Seqirus portfolio CI